The "Confluence of Minds — 2026 Academic Summit on Frontiers in Neurodevelopment and Mental Health & Second Annual Meeting of the Feihe–Harvard BCH Brain Development Foundation" was held March 30–31 at the Duke-NUS Medical School in Singapore. The two-day summit was jointly organized by the BCH-Feihe Pediatric Brain Development Initiative, the Neuroscience and Behavioural Disorders Programme at Duke-NUS Medical School, Boston Children's Hospital, and Harvard Medical School.
The gathering brought together leading scientists from nearly 20 institutions worldwide, including Harvard, Yale, Tsinghua, Fudan, and Duke-NUS Medical School. Attendees included members of the U.S. National Academy of Sciences, academicians of the Chinese Academy of Sciences, and the editor-in-chief of "Nature Neuroscience."
The summit reflects Feihe's role as a long-term supporter and active organizer of international scientific dialogue on early brain development and mental health — areas the company views as central to human wellbeing across the lifecycle.
"Feihe is willing to share its development achievements with the world and bring scientific nutrition to all humanity," said Leng Youbin, Chairman of Feihe, at the summit.
One attending member of the U.S. National Academy of Sciences noted that the collaboration extends beyond funding: "Feihe is not only a supporter of scientific research — it is a driver of the global innovation chain. Our collaboration will create immeasurable value for human health."
A Global Research Ecosystem Built Over Decades
Feihe's engagement with the international scientific community is the product of sustained, long-term investment. Over the past decade, the company has established research partnerships with more than 40 leading institutions across seven countries, building a network that spans basic research, process innovation, product development, and clinical validation.
That commitment extends to proprietary technology. Feihe's "Fresh Milk Protein Extraction Technology" enables the direct extraction of active proteins — including casein, α-lactalbumin, and lactoferrin — from fresh milk sourced from the company's own farms. Feihe has achieved full in-house production capability for 11 core ingredients, a foundation that is enabling the company to extend infant-grade nutritional standards across the full human lifecycle.
Having led China's infant formula market in sales for seven consecutive years, Feihe is actively broadening its portfolio — from new infant formula lines to children's nutrition products such as Supernova Cheese, to small-molecule milk protein powders designed for middle-aged and elderly consumers.
Expanding Internationally
Feihe's research investments are translating into commercial expansion. In North America, the company established Canada's first infant formula manufacturing facility, with products now carried by more than 1,600 major retailers across the region. In Southeast Asia, Feihe entered the Philippines with its AceKid Activegro pure fresh milk formula — now available in nearly 500 stores and covering approximately 80% of the country's high-end retail network. The AceKid Activegro line recently received regulatory approval in Indonesia, making Feihe the first Chinese infant formula brand to enter that market.
